Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
62 stopped studies mapped to Encapsulated Glioma and descendants · 89% state a reason
Over the 62 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API ().
reasonMatches| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06639607 | PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and…(PRiME II) | Phase 1 / Phase 2 | suspended | Oct 15, 2024 | Washington University School of Medicine | Drugs/Equipment Unavailable | Other (stated, no rule matched) |
| NCT03952598 | Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of… | Phase 2 | suspended | May 16, 2019 | National Cancer Institute (NCI) | Study on hold pending possible updates with the team. | Other (stated, no rule matched) |
| NCT03173950 | Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers | Phase 2 | terminated | Jun 2, 2017 | National Cancer Institute (NCI) | Support was withdrawn from study resulting in early termination of study. Investigator had to close… | Drug supply |
| NCT03796273 | Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer… | Early Phase 1 | terminated | Jan 8, 2019 | Wake Forest University Health Sciences | Low accruals | Enrollment / accrual |
| NCT04105374 | Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual… | Phase 2 / Phase 3 | withdrawn | Sep 26, 2019 | NRG Oncology | NCI approval withdrawn | Other (stated, no rule matched) |
| NCT05513859 | Investigational Imaging Technique During Brain Surgery | N/A | suspended | Aug 24, 2022 | Emory University | Temporarily Closed | Other (stated, no rule matched) |
| NCT05934630 | Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young… | — | terminated | Jul 7, 2023 | Pediatric Brain Tumor Consortium | The NCI will not extend the PBTC grant beyond March 31, 2026. | Other (stated, no rule matched) |
| NCT01795313 | Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With… | Phase 1 | terminated | Feb 20, 2013 | James Felker | Closed supratentorial arm prematurely secondary to lack of enrollment | Enrollment / accrual |
| NCT06466798 | Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and… | Phase 1 | withdrawn | Jun 20, 2024 | Jeffrey Treiber | Inability to find participants meeting eligibility critieria | Other (stated, no rule matched) |
| NCT04985604 | Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors | Phase 2 | terminated | Aug 2, 2021 | Day One Biopharmaceuticals, Inc. | Sponsor decision | Sponsor / business decision |
| NCT01849952 | Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas | — | terminated | May 9, 2013 | Dartmouth-Hitchcock Medical Center | Study was administratively closed by IRB | Other (stated, no rule matched) |
| NCT07121829 | Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and… | Phase 1 | terminated | Aug 14, 2025 | Day One Biopharmaceuticals, Inc. | Sponsor decision | Sponsor / business decision |
| NCT06038760 | Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours…(PEAR-GLIO) | — | terminated | Sep 15, 2023 | Ourotech, Inc. | Lack of funding | Funding |
| NCT05297864 | PARP Inhibition for Gliomas (PI-4G or π4g)(OU-SCC-PI-4G) | Phase 2 | terminated | Mar 28, 2022 | University of Oklahoma | Funder terminated funding. | Funding |
| NCT03095248 | Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors(SEL-TH-1601) | Phase 2 | terminated | Mar 29, 2017 | Children's Hospital Medical Center, Cincinnati | Results review of patient data | Other (stated, no rule matched) |
| NCT04544007 | A Phase II Trial of Poly-ICLC for Low-Grade Gliomas(NF111) | Phase 2 | terminated | Sep 10, 2020 | University of Alabama at Birmingham | The closure of the study is due to the lack of enrollment and the lack of evaluable patients. | Enrollment / accrual |
| NCT02722512 | Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine | Phase 1 | terminated | Mar 30, 2016 | Ann & Robert H Lurie Children's Hospital of Chicago | Lack of substantial evidence for immune responses in response to vaccination. | Other (stated, no rule matched) |
| NCT01247922 | Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol… | Phase 2 | terminated | Nov 25, 2010 | OSI Pharmaceuticals | In a pre-planned interim analysis, OSI-774-205 met futility for efficacy with no safety concerns.… | Safety / toxicity |
| NCT02372409 | Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain… | Phase 2 | terminated | Feb 26, 2015 | Washington University School of Medicine | Low accruals and competing clinical trials | Enrollment / accrual |
| NCT03973918 | Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG(BRAF) | Phase 2 | terminated | Jun 4, 2019 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCI decided to terminate ABTC Consortium due to NCI moving in different direction for Brain Cancer | Other (stated, no rule matched) |
| NCT03990597 | StrataXRT in Preventing Radiation Dermatitis in Pediatric Patients Undergoing Radiation… | Phase 1 | withdrawn | Jun 19, 2019 | M.D. Anderson Cancer Center | Per PI | Other (stated, no rule matched) |
| NCT02924038 | A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II… | Phase 1 | terminated | Oct 5, 2016 | Nicholas Butowski | Industry sponsor decision | Sponsor / business decision |
| NCT03593993 | A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas | — | terminated | Jul 20, 2018 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | low accrual and lack of funds | Enrollment / accrual |
| NCT04650204 | Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and… | Phase 4 | terminated | Dec 2, 2020 | Mayo Clinic | The funding sponsor, EISAI, sold the US rights to the medication and can no longer provide it to… | Funding |
| NCT04730349 | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in…(PIVOT IO 020) | Phase 1 / Phase 2 | terminated | Jan 29, 2021 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT05222165 | Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or…(NEWEL) | Phase 1 / Phase 2 | withdrawn | Feb 3, 2022 | Helsinn Healthcare SA | The company decided to interrupt the development of the drug in all oncological indications | Sponsor / business decision |
| NCT02654340 | Biomarkers for Tuberous Sclerosis Complex (BioTuScCom)(TuScCom) | — | terminated | Jan 13, 2016 | CENTOGENE GmbH Rostock | Study no longer pursued. | Other (stated, no rule matched) |
| NCT05233215 | GROW (Glioma Specialists Reaching Out With Support) Support | N/A | withdrawn | Feb 10, 2022 | Dana-Farber Cancer Institute | Funding | Funding |
| NCT02023905 | Everolimus With and Without Temozolomide in Adult Low Grade Glioma | Phase 2 | terminated | Dec 30, 2013 | University of California, San Francisco | Sponsor decision | Sponsor / business decision |
| NCT03649464 | Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants | Phase 1 / Phase 2 | withdrawn | Aug 28, 2018 | Oblato, Inc. | Planned to execute the new Oral OKN-007 clinical trial with modified study plan soon. This Study… | Other (stated, no rule matched) |
| NCT01884740 | Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial… | Phase 1 / Phase 2 | terminated | Jun 24, 2013 | Weill Medical College of Cornell University | The study was prematurely closed in December 2021 due to low accrual. | Enrollment / accrual |
| NCT03727841 | Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and… | Phase 2 | terminated | Nov 1, 2018 | National Cancer Institute (NCI) | The pharmaceutical company decided to close their program evaluating the study agent, Marizomib. | Sponsor / business decision |
| NCT01452854 | Ovarian Aging in Low Grade Glioma (LGG) Treated With Temozolomide(OVA-LGG) | — | terminated | Oct 17, 2011 | University of California, San Francisco | Low recruitment, sponsor withdrew funding. | Enrollment / accrual |
| NCT00003479 | Antineoplaston Therapy in Treating Patients With Ependymoma | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | Slow accrual | Enrollment / accrual |
| NCT03763422 | Trial in Low Grade Glioma Patients: Wait or Treat(IWOT) | Phase 3 | terminated | Dec 4, 2018 | European Organisation for Research and Treatment of Cancer - EORTC | Poorly recruiting | Enrollment / accrual |
| NCT03906448 | FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma(FORWARD) | Phase 2 | terminated | Apr 8, 2019 | University of Florida | The study was terminated because the Study Chair/IDE Sponsor and Novocure determined that… | Other (stated, no rule matched) |
| NCT03353896 | NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk Oligodendroglioma | N/A | withdrawn | Nov 27, 2017 | University of Southern California | Insufficient accrual | Enrollment / accrual |
| NCT03014804 | Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in… | Phase 2 | withdrawn | Jan 9, 2017 | Jonsson Comprehensive Cancer Center | Final contract negotiations | Other (stated, no rule matched) |
| NCT02764151 | First in Patient Study for PF-06840003 in Malignant Gliomas | Phase 1 | terminated | May 6, 2016 | Pfizer | Sponsor decided to prematurely terminate the study and not to pursue marketing approval for the… | Sponsor / business decision |
| NCT02684071 | Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive… | Phase 2 | terminated | Feb 17, 2016 | Nicklaus Children's Hospital f/k/a Miami Children's Hospital | Lack of additional funding; patients (3) no longer receiving intervention. | Funding |
| NCT01117155 | A Pilot Study Evaluating 18F-L-Thymidine (FLT) PET Imaging in Children With Gliomas | — | withdrawn | May 5, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00031538 | Genetic Analysis of Brain Tumors | — | terminated | Mar 7, 2002 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01251913 | A Pilot Study of Inpatient Hospice With Procurement of Brain Tumor Tissue on Expiration… | — | terminated | Dec 2, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00035373 | Eligibility Screening of Patients With Central Nervous System Tumors for the National… | — | terminated | May 3, 2002 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02689336 | Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory… | Phase 2 | withdrawn | Feb 23, 2016 | Washington University School of Medicine | Could not recruit any participants | Enrollment / accrual |
| NCT01103375 | Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant… | Phase 1 | terminated | Apr 14, 2010 | Wake Forest University Health Sciences | Slow accrual | Enrollment / accrual |
| NCT01836549 | Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors | Phase 2 | terminated | Apr 22, 2013 | Pediatric Brain Tumor Consortium | Due to several intracranial hemorrhages and recommendation by the PBTC DSMB. | Other (stated, no rule matched) |
| NCT01281982 | (11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas | — | terminated | Jan 24, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01234805 | Yoga Therapy in Treating Patients With Malignant Brain Tumors | N/A | terminated | Nov 4, 2010 | Wake Forest University Health Sciences | Slow Accruals | Enrollment / accrual |
| NCT00003471 | Antineoplaston Therapy in Treating Patients With Low-Grade Astrocytoma | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | Slow accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 19 days agoSource updated Sep 11, 2026source: clinicaltrials